Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

This study looks at whether empagliflozin — a medication normally used for diabetes and heart disease — can reduce the amount of glucose (sugar) absorbed through the peritoneal membrane in people who are on peritoneal dialysis for kidney failure. Excess glucose absorption during dialysis can cause long-term damage to the peritoneal membrane, so finding ways to reduce it could be beneficial. Adults over 18 who have been stable on peritoneal dialysis for more than 3 months may be eligible, though people with type 1 diabetes, recent peritonitis infections, or severe anemia are excluded. Participation involves taking the study drug or a placebo during clinic visits and undergoing a standard peritoneal equilibration test (PET) at several time points over about 9 weeks. This summary was generated with AI assistance to help patients understand the study in plain language.